ArticleScientific reports2025
Clinical presentation and outcomes of children hospitalized with sickle cell anemia at Gulu regional referral hospital, Uganda: a retrospective cross-sectional study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Sickle cell anemia (SCA) is a significant public health challenge, particularly in sub-Saharan Africa, where 80% of affected individuals reside. This study aimed to evaluate the clinical presentation and outcomes of children with SCA hospitalized at GRRH. A retrospective cross-sectional study was conducted, reviewing medical records of children aged 0–18 years hospitalized with SCA at Gulu Regional Referral Hospital (GRRH) between January 2019 and June 2024. Data on demographics, clinical presentations, interventions, and outcomes were collected and analyzed with descriptive statistics in Stata 18.0. Of 126 children enrolled, the median age was 7 years (IQR 3–10 years), with 55.6% male (n = 70). Painful crises (86.5%, n = 109) and fever (66.7%, n = 84) were the most common presentations, followed by jaundice (21.4%, n = 27) and respiratory distress (8.7%, n = 11). Most children (98.4%, n = 124) had hospital stays of less than one week, with 94.4% (n = 119) achieving complete recovery. Treatment included folic acid supplementation (99.2%, n = 125), antibiotics (96.8%, n = 122), and hydroxyurea (14.3%, n = 18). Mortality was 3.9% (n = 5), and 1.6% (n = 2) were transferred. Painful crises and fever were predominant clinical features, with high recovery rates and short hospital stays suggesting relatively favourable outcomes at GRRH. Mortality was 3.9%, which is lower than or comparable to reported inpatient mortality rates of 4–12% for paediatric sickle cell anaemia in other sub-Saharan African settings. However, limited hydroxyurea use highlights access barriers. Strengthening SCA healthcare policies, increasing hydroxyurea availability, and further research into severe cases are recommended to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.